National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting, 36112 [2019-15879]
Download as PDF
<![CDATA[
36112
Federal Register / Vol. 84, No. 144 / Friday, July 26, 2019 / Notices
jbell on DSK3GLQ082PROD with NOTICES
legitimate access to controlled
substances, including opioids, while
also preventing diversion and abuse, as
well as how federal, state, local, and
tribal entities can collaborate to address
these issues.
DATES: Comments must be received at
one of the addresses provided below, no
later than 5 p.m. on August 26, 2019.
ADDRESSES: Written comments can be
provided by email, fax or U.S. mail.
Email: EPAEDEAreport@hhs.gov.
Fax: (202) 690–5882.
Mail: U.S. Department of Health and
Human Services, Office of the Assistant
Secretary for Planning and Evaluation,
Office of Science and Data Policy, Attn:
EPAEDEA Report Feedback, 200
Independence Avenue SW, Room 434E,
Washington, DC 20201.
FOR FURTHER INFORMATION CONTACT:
Jessica White, Office of the Assistant
Secretary for Planning and Evaluation,
202–690–7100.
SUPPLEMENTARY INFORMATION:
I. Background
Section 3 of the Ensuring Patient
Access and Effective Drug Enforcement
Act of 2016 (EPAEDEA), Public Law
114–145, called for the Department of
Health and Human Services, acting
through the Commissioner of Food and
Drugs, the Administrator of the
Substance Abuse and Mental Health
Services Administration, the Director of
the Agency for Healthcare Research and
Quality, and the Director of the Centers
for Disease Control and Prevention, and
in coordination with the Administrator
of the Drug Enforcement Administration
and in consultation with the Secretary
of Defense and the Secretary of Veterans
Affairs, to submit a report to Congress
that identifies:
• Obstacles to legitimate patient access
to controlled substances
• issues with diversion of controlled
substances
• how collaboration between Federal,
State, local, and tribal law
enforcement agencies and the
pharmaceutical industry can benefit
patients and prevent diversion and
abuse of controlled substances;
• the availability of medical education,
training opportunities, and
comprehensive clinical guidance for
pain management and opioid
prescribing, and any gaps that should
be addressed
• beneficial enhancements to State
prescription drug monitoring
programs, including enhancements to
require comprehensive prescriber
input and to expand access to the
programs for appropriate authorized
users
VerDate Sep<11>2014
17:54 Jul 25, 2019
Jkt 247001
• steps to improve reporting
requirements so that the public and
Congress have more information
regarding prescription opioids, such
as the volume and formulation of
prescription opioids prescribed
annually, the dispensing of such
prescription opioids, and outliers and
trends within large data sets.
The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
II. Solicitation of Comments
EPAEDEA requires that the report
incorporate feedback and
recommendations from the following:
(1) Patient groups; (2) pharmacies; (3)
drug manufacturers; (4) common or
contract carriers and warehousemen; (5)
hospitals, physicians, and other health
care providers; (6) State attorneys
general; (7) Federal, State, local, and
tribal law enforcement agencies; (8)
health insurance providers and entities
that provide pharmacy benefit
management services on behalf of a
health insurance provider; (9) wholesale
drug distributors; (10) veterinarians; (11)
professional medical societies and
boards; (12) State and local public
health authorities; and (13) health
services research organizations.
This RFI is seeking comment from
these stakeholders on the
aforementioned issue areas to be
covered by the report.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Review for: HEAL:
Optimization of Non-addictive Therapies
[Small Molecules and Biologics] to Treat
Pain.
Date: July 26, 2019.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Canopy by Hilton, 940 Rose Avenue,
North Bethesda, MD 20852.
Contact Person: Marilyn Moore-Hoon,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Activities, National Institute of Neurological
Disorders and Stroke, Bethesda, MD 20892,
301–827–9087, mooremar@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
III. Response to Comments
Because of the large number of public
comments we normally receive on
Federal Register documents, we are not
able to acknowledge or respond to them
individually. We will consider all
comments we receive by the date and
time specified in the DATES section of
this preamble.
Dated: July 16, 2019.
Brenda Destro,
Deputy Assistant Secretary for Planning and
Evaluation (HSP).
[FR Doc. 2019–15952 Filed 7–25–19; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended.
Frm 00064
Fmt 4703
[FR Doc. 2019–15879 Filed 7–25–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Immigration and Customs
Enforcement
[OMB Control Number 1653–0043]
BILLING CODE 4150–15–P
PO 00000
Dated: July 19, 2019.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
Sfmt 4703
Agency Information Collection
Activities; Extension of a Currently
Approved Collection: Electronic Funds
Transfer Waiver Request; Comment
Request
U.S. Immigration and Customs
Enforcement, Department of Homeland
Security.
ACTION: 30-Day notice.
AGENCY:
SUMMARY: In accordance with the
Paperwork Reductions Act (PRA) of
1995 the Department of Homeland
Security (DHS), U.S. Immigration and
Customs Enforcement (ICE) will submit
the following Information Collection
Request (ICR) to the Office of
E:\FR\FM\26JYN1.SGM
26JYN1
]]>Agencies
[Federal Register Volume 84, Number 144 (Friday, July 26, 2019)]
[Notices]
[Page 36112]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-15879]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice
of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended.
The grant applications and the discussions could disclose confidential
trade secrets or commercial property such as patentable material, and
personal information concerning individuals associated with the grant
applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; Review for: HEAL: Optimization of
Non-addictive Therapies [Small Molecules and Biologics] to Treat
Pain.
Date: July 26, 2019.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Canopy by Hilton, 940 Rose Avenue, North Bethesda, MD
20852.
Contact Person: Marilyn Moore-Hoon, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural
Activities, National Institute of Neurological Disorders and Stroke,
Bethesda, MD 20892, 301-827-9087, [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.853,
Clinical Research Related to Neurological Disorders; 93.854,
Biological Basis Research in the Neurosciences, National Institutes
of Health, HHS)
Dated: July 19, 2019.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-15879 Filed 7-25-19; 8:45 am]
BILLING CODE 4140-01-P
